drugset / Trial / NCT03744312

Imaging Inflammation in Alzheimer's Disease With 11C-ER176

NCT03744312

Phase 1/2 Completed 9 enrolled Columbia University
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This study is being done to learn about inflammation in the brain of those with Alzheimer's disease (AD). The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. Both patients (with either mild cognitive impairment (MCI) or Alzheimer's disease) and healthy controls (participants without memory complaints or impairment) will be included in this study.

Timeline

Start
2018-09-10
Primary completion
2022-07-20
Completion
2022-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject 11C-ER176 Diagnostic / imaging agent Other
Subject Florbetaben Diagnostic / imaging agent Other

Indications